Immunoassay Market worth $44.49 billion by 2031
The report "Immunoassay Market by Product (Reagents & Kits, Analyzers), Technology (ELISA, IFA, Western Blot), Specimen (Blood, Saliva), Application (Infectious Diseases, Endocrinology, Cardiology), End User (Hospital, Blood Bank) & Region – Global Forecast to 2031", is projected to grow from USD 31.65 billion in 2026 and to reach USD 44.49 billion by 2031, at a Compound Annual Growth Rate (CAGR) of 7.0% during the forecast period.
Browse 550 market data tables and 70 figures spread through 500 pages and in-depth TOC on the "Immunoassay Market by Product (Reagents & Kits, Analyzers), Technology (ELISA, IFA, Western Blot), Specimen (Blood, Saliva), Application (Infectious Diseases, Endocrinology, Cardiology), End User (Hospital, Blood Bank) & Region – Global Forecast to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/immunoassay-market-436.html
The global immunoassay market is primarily driven by the rising incidence of chronic and infectious diseases, the growing use of immunoassays in oncology and diagnostics, and the growing geriatric population requiring regular disease screening and monitoring. Increasing demand for blood screening, expansion of biotechnology and biopharmaceutical industries, supportive government initiatives, and the growing adoption of immunoassay-based point-of-care and rapid testing are further supporting market growth. The increasing consumption of drugs, alcohol, and cannabis is also contributing to demand for immunoassay-based screening and testing. Growth in emerging economies, increasing focus on companion diagnostics, development of condition-specific biomarkers and tests, integration of microfluidics, and advancements in immunoassay technologies are expected to create additional opportunities. However, stringent approval requirements for immunoassay instruments and consumables, technical challenges associated with immunoassay kits, antibody quality and design limitations, and a shortage of skilled professionals may constrain market growth.
“By technology, the chemiluminescence immunoassay (CLIA) segment accounted for the largest share of the global immunoassay market in 2025.”
Based on technology, the global immunoassay market is segmented into ELISA, chemiluminescence immunoassay (CLIA), immunofluorescence assay (IFA), rapid tests, western blotting, and other technologies. Among these, CLIA is expected to account for the largest share of the market because of its high sensitivity and specificity, faster turnaround time, broad dynamic range, and compatibility with automated and high-throughput testing platforms. The increasing demand for rapid, accurate diagnostic testing, coupled with the growing adoption of automated immunoassay systems across clinical laboratories and healthcare settings, further supports the widespread use of CLIA globally.
“By end user, hospitals & clinics accounted for the largest share of the immunoassay market in 2025.”
By end user, the immunoassay market is segmented into hospitals & clinics, clinical laboratories, blood banks, and home care settings. In 2025, hospitals & clinics accounted for the largest share of the market, mainly because of their central role in diagnostic testing across a broad range of acute and chronic conditions. The availability of advanced immunoassay platforms, high patient volumes, and the increasing adoption of automated and multiplexed testing systems further support the use of immunoassays in these settings. In addition, integrating immunoassay testing into routine diagnostics, disease screening, and patient monitoring is expected to sustain demand for immunoassay products in hospitals & clinics.
“North America accounted for the largest share of the immunoassay market in 2025.”
North America held the largest share of the immunoassay market in 2025, supported by well-established diagnostic companies, advanced healthcare infrastructure, and high adoption of sophisticated diagnostic technologies. The US was a major contributor to the region’s market share, driven by strong demand for immunoassay-based testing across clinical and research settings. The increasing burden of chronic and infectious diseases, along with the widespread adoption of automated and point-of-care immunoassay platforms, further supported market growth in the region.
In addition, strong collaboration among regulatory agencies, healthcare institutions, and research organizations has supported advancements in immunoassay technologies and diagnostic testing standards. Regulatory oversight and research initiatives have improved assay validation, accuracy, traceability, and reproducibility, facilitating the adoption of advanced immunoassay technologies across healthcare settings. These factors, combined with continued investments in diagnostic infrastructure and technological advancements, are expected to reinforce North America’s position as a major market for immunoassay technologies during the forecast period.
Major players operating in the immunoassay market are Abbott Laboratories (US), F. Hoffmann-La Roche (Switzerland), Siemens Healthineers (Germany), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Revvity (US), Becton, Dickinson and Company (US), DiaSorin S.p.A. (Italy), and Bio-Rad Laboratories (US).
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Immunoassay Market
- What will your New Revenue Sources be
- Who will be your Top Customer; what will make them switch
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
